[Experience in using a combination of olivomycin with cyclophosphane in treating malignant testicular tumors of heterogeneous structure].
Clinical trials of the combination of olivomycin with cyclophosphamide were performed on 41 patients with testicle tumours of heterogenous structure. Objective effects were observed in 70.7 per cent of the cases, an effect higher than 50 per cent was recorded in 46.3 per cent of the patients and complete regression of the tumours was achieved in 17.1 per cent of the cases. The combination of olivomycin with cyclophosphamide was well tolerated by the patients. The most frequent side effects of the combination were leucopenia, thrombocytopenia, nausea and vomiting.
D000328:Adult; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D009848:Olivomycins / Q000008:administration & dosage* / Q000009:adverse effects; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D009848:Olivomycins; D003520:Cyclophosphamide
Opyt primeneniia kombinatsii olivomitsina s tsiklofosfanom pri lechenii zlokachestvennykh opukholeĭ iaichka neodnorodnogo stroeniia.